Showing results (661-670 of 678) with videos related to

Sort By:
Pageof 68
The Lancet. Oncology|August 26, 2017
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialMarianne E Pavel, Simron Singh, Jonathan R Strosberg, et al.
JAMA Oncology|April 7, 2022
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical TrialDaniel M Halperin, Suyu Liu, Arvind Dasari, et al.
Oncology|October 7, 2020
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma PatientsReham Abdel-Wahab, Manal M Hassan, Bhawana George, et al.
National Science Review|July 10, 2026
A system capable of verifiably and privately screening global DNA synthesisCarsten Baum, Jens Berlips, Walther Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 14, 2015
Neuroendocrine tumors, version 1.2015Matthew H Kulke, Manisha H Shah, Al B Benson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized studyY K Shi, L Wang, B H Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2019
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNAAhmed O Kaseb, Nora S Sánchez, Shiraj Sen, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics|November 6, 2018
[A multicenter study of reference intervals for 15 laboratory parameters in Chinese children]X H Zhong, J Ding, J H Zhou, et al.
Zhonghua Yi Xue Za Zhi|January 29, 2026
[Analysis of the efficacy and safety of magaldrate granules quadruple therapy in the treatment of Helicobacter pylori infection]X H Dong, J X Liu, W Gao, et al.
The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.
Pageof 68